ArticlePloS one2025
Salivary microbiome in peritoneal dialysis patients with and without sarcopenia: A pilot study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate salivary microbiota composition in end-stage kidney disease (ESKD) patients with sarcopenia (SESKD), ESKD patients without sarcopenia (NSESKD), and individuals without chronic kidney disease (control group). MATERIALS AND
methodsThirty-three participants were enrolled: 10 SESKD patients, 12 NSESKD patients, and 11 controls. Demographic data, oral examinations, and unstimulated saliva samples were collected. Salivary bacterial microbiomes were analyzed using high-throughput sequencing targeting the V3-V4 region of the bacterial 16S rRNA gene.
resultsThe overall bacterial abundance and distribution were significantly higher in the SESKD and NSESKD groups compared to the control group (p < 0.05), with no significant differences between the SESKD and NSESKD groups. ESKD, educational level, and muscle strength were significantly associated with variations in the salivary microbiome composition. Analysis of bacterial abundance revealed a shift in trends as the disease combined from control to NSESKD and SESKD group, respectively, across 7 genera: Actinobacillus, TM7x, Capnocytophaga, Neisseria, and Leptotrichia increased in abundance, while Actinomyces and Atopobium decreased. Linear discriminant analysis effect size (LEfSe) identified Leptotrichia as a potential biomarker for ESKD (both with and without sarcopenia).
conclusionESKD condition impacted microbial composition, with minimal influence from sarcopenia. Specifically, Leptotrichia was notably higher in the ESKD group.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.